Franklin Resources Inc. Has $1.97 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Franklin Resources Inc. lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 177.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 263,748 shares of the biotechnology company’s stock after acquiring an additional 168,790 shares during the quarter. Franklin Resources Inc. owned approximately 0.13% of BioCryst Pharmaceuticals worth $1,968,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Sanctuary Advisors LLC increased its position in shares of BioCryst Pharmaceuticals by 78.3% during the third quarter. Sanctuary Advisors LLC now owns 47,389 shares of the biotechnology company’s stock valued at $360,000 after acquiring an additional 20,818 shares during the last quarter. SkyView Investment Advisors LLC grew its stake in BioCryst Pharmaceuticals by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 3,000 shares during the period. Geode Capital Management LLC increased its position in shares of BioCryst Pharmaceuticals by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after purchasing an additional 127,708 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter worth $819,000. Finally, Two Sigma Advisers LP boosted its holdings in shares of BioCryst Pharmaceuticals by 13.6% in the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock worth $16,576,000 after buying an additional 261,500 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $7.72 on Friday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88. The stock’s fifty day moving average price is $7.64 and its two-hundred day moving average price is $7.45. The company has a market cap of $1.60 billion, a P/E ratio of -12.66 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. During the same period last year, the company posted ($0.19) EPS. The business’s revenue for the quarter was up 35.1% on a year-over-year basis. On average, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on BCRX. Needham & Company LLC restated a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Barclays raised their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $15.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.